18f -胆碱PET/CT在前列腺癌患者中是否有作用?

Q4 Medicine
M. Hodolič
{"title":"18f -胆碱PET/CT在前列腺癌患者中是否有作用?","authors":"M. Hodolič","doi":"10.2298/AOO1204084H","DOIUrl":null,"url":null,"abstract":"Prostate cancer is the ninth-most-common cancer in the world and the most common life-threatening cancer affecting men in the western countries. More than 80% of men will develop prostate cancer by the age of 80. Physiologically, choline is a component of cell membranes. It presents a high affinity for malignant prostate tissue. Choline, labeled with 11C or 18F is the essential part of most sensitive nuclear medicine procedure for imaging of spread of prostate cancer today. 11C-choline is preferred due to lower urinary excretion and patient exposure. Due to shorter half-life time of 11C (20 minutes), 18F-choline (half-life time of 110 minutes) is more useful for possible distribution to centers lacking on-site cyclotron. The sensitivity of 18F-choline PET/CT to detect prostate cancer preoperatively is 73%, greater than with 18F-FDG PET/CT (31%). Also, the accuracy is greater with 18F-choline PET/ CT (67%) than using 18F-FDG PET/CT (53%). The major goal of pretherapeutic imaging with 18F-choline PET/CT is detection of loco-regional and distant metastases. The exact pretherapeutic diagnosis and staging are mandatory, because the tumor treatment must be selected in strict dependence on the clinical tumor stage and risk profile. In patients with biochemical relapse after the radical prostatectomy or radiotherapy of prostate cancer, 18F-choline PET/CT represents a noninvasive, whole body study that allows disease localization. Detection sensitivity is negatively correlated with serum PSA concentration (ng/ml) and positively correlated with Gleason score. 18F-choline PET/CT is becoming the essential imaging modality in patients with prostate cancer to demonstrate spread of the disease preoperatively and to detect local and distant recurrent disease after radical prostatectomy or radiotherapy.","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2298/AOO1204084H","citationCount":"0","resultStr":"{\"title\":\"Is there the role of 18F-choline PET/CT in prostate cancer patients?\",\"authors\":\"M. Hodolič\",\"doi\":\"10.2298/AOO1204084H\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Prostate cancer is the ninth-most-common cancer in the world and the most common life-threatening cancer affecting men in the western countries. More than 80% of men will develop prostate cancer by the age of 80. Physiologically, choline is a component of cell membranes. It presents a high affinity for malignant prostate tissue. Choline, labeled with 11C or 18F is the essential part of most sensitive nuclear medicine procedure for imaging of spread of prostate cancer today. 11C-choline is preferred due to lower urinary excretion and patient exposure. Due to shorter half-life time of 11C (20 minutes), 18F-choline (half-life time of 110 minutes) is more useful for possible distribution to centers lacking on-site cyclotron. The sensitivity of 18F-choline PET/CT to detect prostate cancer preoperatively is 73%, greater than with 18F-FDG PET/CT (31%). Also, the accuracy is greater with 18F-choline PET/ CT (67%) than using 18F-FDG PET/CT (53%). The major goal of pretherapeutic imaging with 18F-choline PET/CT is detection of loco-regional and distant metastases. The exact pretherapeutic diagnosis and staging are mandatory, because the tumor treatment must be selected in strict dependence on the clinical tumor stage and risk profile. In patients with biochemical relapse after the radical prostatectomy or radiotherapy of prostate cancer, 18F-choline PET/CT represents a noninvasive, whole body study that allows disease localization. Detection sensitivity is negatively correlated with serum PSA concentration (ng/ml) and positively correlated with Gleason score. 18F-choline PET/CT is becoming the essential imaging modality in patients with prostate cancer to demonstrate spread of the disease preoperatively and to detect local and distant recurrent disease after radical prostatectomy or radiotherapy.\",\"PeriodicalId\":35645,\"journal\":{\"name\":\"Archive of Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2298/AOO1204084H\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archive of Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2298/AOO1204084H\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archive of Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2298/AOO1204084H","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

前列腺癌是世界上第九大常见癌症,也是西方国家男性最常见的危及生命的癌症。超过80%的男性在80岁时会患上前列腺癌。生理上,胆碱是细胞膜的一种成分。它对恶性前列腺组织有很高的亲和力。胆碱标记为11C或18F,是当今最敏感的前列腺癌扩散成像核医学程序的重要组成部分。11c -胆碱是首选,因为尿排泄量少,患者暴露少。由于11C的半衰期较短(20分钟),18f -胆碱(110分钟)更有利于可能分布到缺乏现场回旋加速器的中心。术前18f -胆碱PET/CT检测前列腺癌的敏感性为73%,高于18F-FDG PET/CT(31%)。此外,使用18f -胆碱PET/CT(67%)比使用18F-FDG PET/CT(53%)的准确性更高。18f -胆碱PET/CT治疗前成像的主要目的是检测局部区域和远处转移。准确的治疗前诊断和分期是必须的,因为必须严格依赖于临床肿瘤分期和风险特征来选择肿瘤治疗。在前列腺癌根治性前列腺切除术或放疗后生化复发的患者中,18f -胆碱PET/CT代表了一种无创的全身研究,允许疾病定位。检测灵敏度与血清PSA浓度(ng/ml)呈负相关,与Gleason评分呈正相关。18f -胆碱PET/CT正在成为前列腺癌患者术前显示疾病扩散和根治性前列腺切除术或放疗后发现局部和远处复发疾病的基本成像方式。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Is there the role of 18F-choline PET/CT in prostate cancer patients?
Prostate cancer is the ninth-most-common cancer in the world and the most common life-threatening cancer affecting men in the western countries. More than 80% of men will develop prostate cancer by the age of 80. Physiologically, choline is a component of cell membranes. It presents a high affinity for malignant prostate tissue. Choline, labeled with 11C or 18F is the essential part of most sensitive nuclear medicine procedure for imaging of spread of prostate cancer today. 11C-choline is preferred due to lower urinary excretion and patient exposure. Due to shorter half-life time of 11C (20 minutes), 18F-choline (half-life time of 110 minutes) is more useful for possible distribution to centers lacking on-site cyclotron. The sensitivity of 18F-choline PET/CT to detect prostate cancer preoperatively is 73%, greater than with 18F-FDG PET/CT (31%). Also, the accuracy is greater with 18F-choline PET/ CT (67%) than using 18F-FDG PET/CT (53%). The major goal of pretherapeutic imaging with 18F-choline PET/CT is detection of loco-regional and distant metastases. The exact pretherapeutic diagnosis and staging are mandatory, because the tumor treatment must be selected in strict dependence on the clinical tumor stage and risk profile. In patients with biochemical relapse after the radical prostatectomy or radiotherapy of prostate cancer, 18F-choline PET/CT represents a noninvasive, whole body study that allows disease localization. Detection sensitivity is negatively correlated with serum PSA concentration (ng/ml) and positively correlated with Gleason score. 18F-choline PET/CT is becoming the essential imaging modality in patients with prostate cancer to demonstrate spread of the disease preoperatively and to detect local and distant recurrent disease after radical prostatectomy or radiotherapy.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Archive of Oncology
Archive of Oncology Medicine-Oncology
CiteScore
0.60
自引率
0.00%
发文量
5
审稿时长
12 weeks
期刊介绍: Archive of Oncology is an international oncology journal that publishes original research, editorials, review articles, case (clinical) reports, and news from oncology (medical, surgical, radiation), experimental oncology, cancer epidemiology, and prevention. Letters are also welcomed. Archive of Oncology is covered by Biomedicina Vojvodina, Biomedicina Serbica, Biomedicina Oncologica, EMBASE/Excerpta Medica, ExtraMED and SCOPUS.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信